Atul Saran, JD, MBA

Chief Executive Officer

Atul has more than 20 years experience in biopharma. Prior to IntegerBio, he held several Executive Vice President roles at Emergent BioSolutions from May 2017 through March 2023 including Chief Strategy and Development Officer, General Counsel, and Corporate Secretary, with management over a broad portfolio of operational and corporate functions. Previously, he served as the Senior Vice President and General Counsel for MacroGenics, a clinical-stage oncology company from May 2013 through April 2017. Prior to that, he held various positions of increasing responsibility at MedImmune/AstraZeneca from February 2003 through December 2009 culminating as Deputy General Counsel before assuming leadership for global biologics corporate development and venture investing for the AstraZeneca group from January 2010 through January 2014. Before taking an in-house role, Mr. Saran was a practicing attorney in the Hogan & Hartson Business & Finance Group from April 1999 through January 2003.

Atul holds an MBA from the MIT Sloan School of Management, a JD from the University of Illinois College of Law, a BS in Biological Sciences from Stanford University, and completed all coursework and Step 1 of the USMLE towards an MD from the University of Illinois. He currently serves as a director on the board of Proniras and has previously served as a director on several board of directors including Arriva, VentiRx, and Xencor.

Wade Blair, PhD

Chief Scientific Officer

Wade has 25 years of industry experience in roles of increasing responsibility at pharmaceutical companies including AstraZeneca, Gilead, Merck, Genentech, Pfizer and Bristol-Myers Squibb. During the course of his career, he has led multiple drug discovery programs that progressed to clinical trials in infectious disease and oncology. He contributed to the discovery and/or development of multiple approved drugs, including the HIV protease inhibitor atazanavir (Reyataz), the HIV non-nucleoside reverse transcriptase inhibitor doravirine (Pifeltro), the HIV attachment inhibitor fostemsavir (Rukobia), the HIV capsid inhibitor, lenacapavir (Sunlenca) the RSV mAb, nirsevimab (Beyfortus), and letermovir (Prevymis), a treatment for cytomegalovirus (CMV) infections. In addition, he has entrepreneurial biotech experience having worked at Gritstone Bio where he led the development of their cancer vaccine platform as the Head of Vaccine Technologies.

Wade received his B.S. in Biology from the University of California, Los Angeles and Ph.D. from the University of California, Irvine. He conducted his postdoctoral research at Duke University studying HIV gene expression.

Christina Griffin, MS, MBA

Chief Business Officer

Christina (Griff) is a seasoned business planning and marketing strategist who has spent over 20 years in the biotechnology/pharmaceutical industry. Previously, she held roles in Business Development, including driving business growth at MedImmune/AstraZeneca focused on negotiating deals for early and late-stage clinical assets, forging joint ventures and acquisitions of intellectual property and innovative technologies across multiple disease areas including Neuroscience, Oncology, Respiratory and Immunology.

Christina also served as a Global Brand Director in AstraZeneca Oncology where she was accountable for driving pre-launch and launch activities, as well as the commercial direction for life-cycle management to maximize contribution to the Oncology business. Previously, she held various roles in commercializing biologics including strategic marketing, launch market development in the US market and managing mature brands at MedImmune (Synagis^®) and Janssen/Centocor (Remicade^®).

After her in-house roles, she advised small and medium-sized biotechs in developing and executing business development strategies, including development of tailored business and growth planning processes for regional and global business units for clients 2017 through 2023.

She holds a Master’s of Business Administration Degree from Georgetown University, with a Master’s Degree in Biology from Massachusetts Institute of Technology and a Bachelor’s of Science degree in Biochemistry from Xavier University of Louisiana.

Jon Shea

Chief Operating Officer

Prior to joining IntegerBio, Jon served for seven years as the VP and Head of IT for MacroGenics. During his tenure, as the company grew from 180 to 430 employees, he transformed the technology capabilities of MacroGenics to support 5+ INDs in 18 months and enabled the company’s first BLA submission. He served on the core commercialization team and helped launch MacroGenics first product in HER2+ Metastatic Breast Cancer. In addition, he supported the build out and operations of a commercial grade manufacturing site, resulting in an FDA licensed facility in 2020.

Previously he served as Senior Director of Commercial Technology at Allergan. At Allergan he focused on aligning new and innovative technologies and services to a unique pipeline of therapeutic and medical aesthetic products. He deployed sales force effectiveness capabilities, digital and social marketing tools and tactics, and first-in-industry customer and consumer loyalty programs, helping to grow revenue from $5.3B to $7.1B in 4 years.

Prior to Allergan, Jon was a management consultant for PricewaterhouseCoopers in their Life Sciences Technology practice. He has an undergraduate degree in Computer Engineering from Virginia Tech.

Katy Strei, MS

Chief People Officer

Prior to joining IntegerBio, Katy served for seven years as the EVP and CHRO for Emergent BioSolutions. In this role she led the efforts to strengthen leadership, culture and talent enabling the company to more than double in size, scale and impact. These efforts included facilitating the evolution of the organization design to address business diversification, designing the talent and people processes and strengthening the leadership bench through talent acquisition and succession planning and successfully integrating multiple acquisitions including two full companies.

Previously she served as VP Talent and Organization Development at MedImmune. In her 9-year tenure there, she inaugurated and built the company’s talent, leadership, engagement and change management capabilities. Prior to joining MedImmune, she served as Director, Leadership and Talent Development, at Fannie Mae, where she led the CEO’s leadership and talent agenda for six years.

Katy serves as a member of the Board of Trustees of Lawrence University in Appleton, Wisconsin. She has an undergraduate degree from Lawrence, a Master’s degree in Organization Development from American University and a certificate in Leadership Coaching from Georgetown University.